3 291

Cited 57 times in

A Randomized Comparison of Platinum Chromium-Based Everolimus-Eluting Stents Versus Cobalt Chromium-Based Zotarolimus-Eluting Stents in All-Comers Receiving Percutaneous Coronary Intervention : HOST–ASSURE (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis–Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen), a Randomized, Controlled, Noninferiority Trial

Authors
 Kyung Woo Park  ;  Si-Hyuck Kang  ;  Hyun-Jae Kang  ;  Bon-Kwon Koo  ;  Byoung-Eun Park  ;  Kwang Soo Cha  ;  Jay Young Rhew  ;  Hui-Kyoung Jeon  ;  Eun-Seok Shin  ;  Ju Hyeon Oh  ;  Myung-Ho Jeong  ;  Sanghyun Kim  ;  Kyung-Kuk Hwang  ;  Jung-Han Yoon  ;  Sung Yun Lee  ;  Tae-Ho Park  ;  Keon Woong Moon  ;  Hyuck-Moon Kwon  ;  Seung-Ho Hur  ;  Jae-Kean Ryu 
Citation
 JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol.63(25) : 2805-2816, 2014 
Journal Title
 JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 
ISSN
 0735-1097 
Issue Date
2014
MeSH
Antineoplastic Agents ; Chromium Alloys ; Chromium Compounds ; Coronary Angiography ; Coronary Stenosis/diagnostic imaging ; Coronary Stenosis/drug therapy* ; Drug-Eluting Stents* ; Everolimus ; Female ; Follow-Up Studies ; Humans ; Immunosuppressive Agents/therapeutic use* ; Male ; Middle Aged ; Percutaneous Coronary Intervention/methods* ; Platelet Aggregation Inhibitors/therapeutic use* ; Platinum Compounds ; Prospective Studies ; Prosthesis Design ; Republic of Korea ; Single-Blind Method ; Sirolimus/analogs & derivatives* ; Sirolimus/therapeutic use ; Treatment Outcome
Keywords
all-comers trial ; clinical outcome ; drug-eluting stent(s) ; percutaneous coronary intervention
Abstract
OBJECTIVES: This study sought to test whether the newly developed platinum chromium (PtCr)-based everolimus-eluting stent (EES) is noninferior to the cobalt chromium (CoCr)-based zotarolimus-eluting stent (ZES) in all-comers receiving percutaneous coronary intervention (PCI). BACKGROUND: PtCr provides improved radial strength, conformability, and visibility compared with the CoCr alloy, but PtCr-based stents have not been tested in a wide range of patients receiving PCI. Also, recent case series have raised the issue of longitudinal stent deformation (LSD) with newer drug-eluting stents. METHODS: We randomly assigned 3,755 all-comers receiving PCI to PtCr-EES or CoCr-ZES. The primary outcome was target lesion failure (TLF) at 1-year post-PCI, defined as the composite of cardiac death, nonfatal target vessel-related myocardial infarction, and ischemia-driven target lesion revascularization. Post-hoc angiographic analysis was performed to qualitatively and quantitatively analyze LSD. RESULTS: At 1 year, TLF occurred in 2.9% and 2.9% of the population in the PtCr-EES and CoCr-ZES groups, respectively (superiority p = 0.98, noninferiority p = 0.0247). There were no significant differences in the individual components of TLF as well as the patient-oriented clinical outcome. Of 5,010 stents analyzed, LSD occurred in 0.2% and 0% in the PtCr-EES and CoCr-ZES groups, respectively (p = 0.104). There was no significant difference in post-deployment stent length ratio between the 2 stents (p = 0.352).
Full Text
http://www.sciencedirect.com/science/article/pii/S0735109714022062
DOI
10.1016/j.jacc.2014.04.013
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kwon, Hyuck Moon(권혁문) ORCID logo https://orcid.org/0000-0001-9901-5015
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/100039
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links